Indianapolis, IN, United States of America

Angelo A Cardoso

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Indiana University. Active years: 2016.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Angelo A Cardoso in Leukemia Treatment

Introduction: Angelo A Cardoso is an accomplished inventor based in Indianapolis, IN (US). He has made significant contributions to the field of medicine, particularly in the treatment of leukemia. His innovative work has led to the development of a patent that addresses critical needs in cancer therapy.

Latest Patents: Angelo A Cardoso holds a patent for "Compounds and methods for treating leukemia." This patent describes various compounds, methods, and pharmaceutical compositions aimed at treating leukemia, specifically acute lymphoblastic leukemia (ALL) in its various forms. His research focuses on the potential of these compounds to improve treatment outcomes for patients suffering from this challenging disease.

Career Highlights: Angelo A Cardoso is affiliated with Indiana University, where he conducts research and collaborates with other experts in the field. His work has garnered attention for its potential impact on leukemia treatment, showcasing his dedication to advancing medical science.

Collaborations: Some of his notable coworkers include Mark R Kelley and Melissa L Fishel. Their collaborative efforts contribute to the ongoing research and development of innovative treatments for leukemia.

Conclusion: Angelo A Cardoso's contributions to leukemia treatment through his patented innovations highlight the importance of research and collaboration in the medical field. His work continues to inspire advancements in cancer therapy, offering hope to many patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…